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AbstrACt 
Objective We aimed to study the epidemiology of the 
prodromal and mild stages of Alzheimer’s disease (AD) 
patients who are eligible for clinical trials with disease-
modifying therapies.
settings We analysed two large complementary 
databases to study the incidence and characteristics of 
this population on a nationwide scope in France from 2014 
to 2018. The National Alzheimer Database contains data 
from 357 memory centres and 90 private neurologists. 
Data from 2014 to 2018 have been analysed.
Participants Patients, 50–85 years old, diagnosed with 
AD who had an Mini-Mental State Exam (MMSE) score of 
≥20 were included. We excluded patients with mixed and 
non-AD neurocognitive disorders.
Primary outcome measure Descriptive statistics of the 
population of interest was the primary measure.
results In the National Alzheimer Database, 550 198 
patients were assessed. Among them, 72 174 (13.1%) 
were diagnosed with AD and had an MMSE ≥20. Using 
corrections for specificity of clinical diagnosis of AD, we 
estimated that about 50 000 (9.1%) had a prodromal 
or mild AD. In the combined electronic clinical records 
database of 11 French expert memory centres, a 
diagnosis of prodromal or mild AD, certified by the use of 
cerebrospinal fluid AD biomarkers, could be established in 
195 (1.3%) out of 14 596 patients.
Conclusions AD was not frequently diagnosed at a 
prodromal or mild dementia stage in France in 2014 to 
2018. Diagnosis rarely relied on a pathophysiological 
marker even in expert memory centres. National 
databases will be valuable to monitor early stage AD 
diagnosis efficacy in memory centres when a disease-
modifying treatment becomes available.
bACkgrOund
Alzheimer’s disease (AD) affects over 
1 million people in France, 35 million 
individuals worldwide, and is one of the 
major challenges of this century for the scien-
tific community.1 Most trials aiming to hinder 
its progression2 are now conducted in its mild 
or even prodromal stage.3–5 Today, an early 
and reliable diagnosis can be made in expert 
centres, which have the necessary resources 
for core AD biomarker analyses, for example, 
cerebrospinal fluid (CSF) analysis.6 
Although some of these trials have already 
shown a lack of treatment efficacy even at 
the mild AD stage,7 8 some undergoing trials 
are testing treatments which showed encour-
aging phase Ib and II results.9 10
In France, the evaluation of patients in 
expert memory clinics is standardised with 
the use of the same neuropsychological tests 
and AD CSF biomarkers (Aß42, tau and phos-
phorylated tau) sampling in clinical practice.
Also, since 2009, a national medical data-
base has been running, the ‘Banque Natio-
nale Alzheimer (BNA)’ (The National 
Alzheimer’s Bank), which was set up as part 
strengths and limitations of this study
 ► Use of two large, multicentric, national databases 
representative of the French healthcare network on 
Alzheimer’s disease.
 ► Absence of data to explain the low rate of early 
Alzheimer’s disease diagnosis in the French national 
Alzheimer database (BNA).
 ► A retrospective design for the electronic record file 
database that does not allow for definitive epidemi-
ological conclusions.
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of the national Alzheimer’s Plan (2008–2012) and has 
already been thoroughly described.11
Our aim was to evaluate the incidence of early AD 
patients who would be eligible for a disease-modifying 
drug trial in a French multicentric retrospective study in 
France between 2014 and 2018.
MethOds
Participants
Two distinct databases were analysed: the first was consti-
tuted for the purpose of this study as a collaborative effort 
from 11 expert memory centres in 2014 when the results 
from the Expedition III trial testing Solanezumab had not 
yet been disclosed. The second database is the ongoing 
BNA in which data are available from 2014 to 2018.
First database: electronic clinical records database
A retrospective multicentric study based on a data-
base from 11 ‘Centres de mémoire, de recherche et de 
ressources’ (Memory, Research and Resource Centres), 
CMRR. In alphabetical order: Dijon, Lille, Nantes, Nancy, 
Nice, Paris-Lariboisière, Paris–Pitié-Salpêtrière, Poitiers, 
Rouen, Strasbourg, Tours) volunteered to participate in 
this study. Each of these centres kept their patient files 
in local electronic clinical records (ECR). The criteria of 
selected patients who would be eligible for a disease-mod-
ifying drug trial were derived from that of the Expedi-
tion III clinical trial ( Clinicaltrials. org: NCT02760602) 
and are in line with the International Working Group 
(IWG) guidelines.4 5 The selected criteria, demographic 
(age, gender, education level, distance to CMRR, care-
giver, referral) and medical data (conventional anti-AD 
treatment, participation in a clinical trial) were recorded 
in this population. Importantly, patients diagnosed with 
mixed dementia were not included in our study, once 
again to mirror the inclusion criteria of the disease-mod-
ifying drugs trials. More specifically, the inclusion criteria 
used in this study were as follows:
 ► Age between 50 and 85 years old.
 ► AD diagnosis based on the IWG-2 criteria operation-
alised as a Free and Cued Selective Reminding test 
(FCSRT) total score <42 AND a CSF phosphorylated 
tau/Aß42 ratio above 0.11.
 ► A mild or prodromal (mild cognitive impairment 
(MCI)) stage of the disease defined by an mini-mental 
state exam (MMSE) score >20 also referred to as ‘early 
AD’.
Exclusion criteria were as follows:
 ► The presence of significant vascular lesions on MRI 
defined as Fazekas and Schmidt leukopathy stage 
3 or the presence of at least one lacunar or territo-
rial infarct or supracentimetric brain haemorrhagic 
sequelae.
 ► The presence of another disease that could better 
explain the symptoms (eg, dementia with Lewy 
bodies and fronto-temporal dementia).
 ► Patient opposition to the use of his/her anonymised 
clinical data for research purposes according to the 
French legislation.
Second database: National Alzheimer database (BNA)
In order to broaden the analysis to a national level and 
extend it over time, the BNA was used to assess the total 
number of clinically diagnosed AD and MCI (divided into 
amnestic (aMCI) and non-amnestic MCI (naMCI) based 
on clinical assessment) individuals in 2014 and 2015 who 
had an MMSE score ≥20. From 2016 onwards, the BNA 
structure changed to integrate the Diagnostic and Statis-
tical Manual fifth edition nomenclature12 and to require 
stating whether CSF biomarkers or genetic features were 
used to ascertain AD diagnosis or not. These results were 
stratified by the type of clinic (primary memory clinic, 
CMRR or private neuro specialist) in which the patients 
had been evaluated. Among the data systematically 
collected, we assessed the Mini Mental State Evaluation 
(MMSE) score13 and the diagnosis according to the Inter-
national Classification of Diseases, 10th Revision.14 AD15 and 
MCI, subcategorised as aMCI or naMCI,3 16 are included 
among the diagnostic categories in the BNA. Both items 
(MMSE and diagnosis) are recorded each time a patient 
consults in one of the 357 participating memory clinics 
(representing 83.6% of all memory clinics in France) 
and 90 private neurology specialists. These clinics are 
divided into two categories: primary memory clinics 
(328/357) and expert memory centres (CMRR 29/357). 
Clinical diagnosis of AD and MCI was used to estimate 
the number of ‘true’ AD cases, taking into account the 
relative specificity for pathophysiologically confirmed AD 
of the different clinically determined diagnostic catego-
ries, that is, 70% for the specificity of the clinical AD17 18 
and 50% for the MCI syndrome.19 BNA was also used to 
assess by comparing patient characteristics between the 
11 CMRR cohort and the 18 that did not participate in 
the study.
Ethics
Both the ECR and BNA databases and their utilisation for 
the purpose of this study were approved by Paris VI Insti-
tutional Review Board and the Commission Nationale 
de l’Informatique et des Libertés (‘National commission 
for informatics and liberty’) responsible in France for 
data protection and use concerning human identity and 
human rights. French Legislation allows the use of anony-
mised clinical data if patients did not specifically object 
to it during consultation. Hence, every patient included 
in this study did not oppose to the use of his/her clinical 
data. However, no written consent was obtained either for 
the ECR or for the BNA database.
Patient and public involvement
Patients were not specifically involved in this study. The 
BNA is publicly disseminated (http://www. innovation- 
alzheimer. fr/ bna- fr/).
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neuropsychological tests
The MMSE13 and the FCSRT20 were collected in the ECR 
database. The FCSRT is a well-validated tool to diagnose 
AD, even at its prodromal stage.21–25 It is recommended in 
the diagnosis of AD by the IWG guidelines.4 5 This test is 
now implemented to screen patients in disease-modifying 
drug trials (eg,  Clinicaltrials. org: NCT02760602). In our 
study, we included patients with a free recall score <20 or 
a total recall score <42.21 The mild or prodromal stages 
were ascertained by an MMSE score >20. In the BNA, only 
the MMSE was available.
Cerebrospinal fluid biomarkers of Ad
CSF was acquired following standard procedures. The 
CSF was obtained by LP between the L3/L4 or L4/L5 
intervertebral space, using a 22-gauge atraumatic needle. 
Five hundred microlitres of CSF were used to perform 
standardised commercially available INNOTEST sand-
wich ELISA according to the manufacturer’s instructions 
(Fujirebio Europe NV, formerly Innogenetics NV). A CSF 
profile of the Alzheimer’s type was defined by a phosphor-
ylated tau/Aß42 ratio >0.11.6 26 CSF biomarkers results 
were available in the ECR database but not in the BNA.
statistical analysis
First, we studied the descriptive statistics of the population 
of interest derived from the analysis performed in the 11 
CMRR. To assess the external validity of our results, we 
compared the BNA data from these 11 CMRR to those of 
the remaining 18 CMRR.
To compare sociodemographic and medical char-
acteristics between the 11 CMRR that volunteered to 
participate in this study and the other 18 CMRR (using 
data that were available for these CMRR in the BNA), 
we performed Student’s t-tests for quantitative variables 
describing means and SD and Χ2 tests for qualitative vari-
ables after an assessment of the Gaussian distribution of 
the continuous variables using the Kolmogorov-Smirnov 
test. All reported p values are two-sided. Statistical anal-
yses and description of the cohort characteristics were 
performed with SAS software V.4.1 (SAS, Cary, North 
Carolina, USA).
results
In 2014, 14 596 patients had a cognitive evaluation in 
one of the 11 participating CMRRs. Among these, 1209 
(8.3%) underwent a lumbar puncture with an analysis of 
AD CSF biomarkers. Among them, 195 (16.1%) had an 
‘early AD’ diagnosis per our chosen criteria, 287 (23.7 
%) had a diagnosis of AD with an MMSE <20; 64 (5.3%) 
had a diagnosis of AD with an MMSE >20 but an FCSRT 
with subscores over our chosen thresholds; 365 (30.2%) 
had a mixed dementia profile (AD and vascular lesions 
237 (65%); AD and suspected Lewy body dementia 84 
(23%); AD and other 44 (12%)) and finally 298 (24.7%) 
had another diagnosis (not AD). Among the 195 patients 
(16.1% of patients who underwent a CSF examina-
tion, 1.3% of all patients) who had a diagnosis of early 
AD according to the IWG-2 criteria, 133 (68.2%) had a 
mild AD dementia and 62 (31.8%) had prodromal AD. 
The proportions of CSF examinations and of mild or 
prodromal AD patients among patients who performed 
a neuropsychological evaluation in the CMRR the same 
year were not statistically different from one CMRR to the 
next as presented in figure 1. The characteristics of these 
early AD patients are presented in table 1.
Figure 1 Incidence of prodromal and mild IWG-2 Alzheimer's disease patients in 2014 in the electronic clinical files of 11 
CMRRs. CMRRs, Centres de mémoire, de recherche et de ressources (Centres for Research and Resources on Memory); IWG, 
International Working Group.
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Interestingly, and although the mean (SD) MMSE 
score was 24.7 (0.2), well above 20, the FCSRT free (10.8 
(0.4)) and total (29.1 (1.8)) recall scores indicated a 
severe amnestic syndrome of the hippocampal type well 
below the chosen cut-off scores of 20 and 42, respec-
tively. The mean (SD) phosphorylated tau/Aß1–42 ratio 
of 0.21 (0.01) was also largely above the threshold of 
0.11 suggesting an unambiguous AD pathophysiological 
process in the participants.
The number of new patients included in the BNA 
between 2014 and 2018 was 550 198. Among them, 72 174 
(13%) were diagnosed with an early AD including MMSE 
≥20. These results are presented in tables 2 and 3. Using 
specificity correction to account for the clinic-patholog-
ical accuracy of AD diagnosis, we estimate that, among 
the 72 174 patients diagnosed with AD between 2014 and 
2018, about 50 000 had a clinical AD with probable AD 
brain pathology.
In the BNA, the rate of CSF biomarker use for AD diag-
nosis varied from 2.1% to 6.7%.
The differences between patients seen in the 11 CMRR 
who volunteered to participate in the detailed study and 
the 18 other CMRR are presented in table 4.
disCussiOn
This observational study in a clinical setting on a national 
scale was specifically designed to estimate the incidence, 
and describe the characteristics, of patients at early stages 
of AD according to recent biomarker-based diagnostic 
criteria. As evidence suggests that disease-modifying 
drugs may be efficient at these stages, such an analysis 
is useful and timely, allowing for the discovery of how 
many patients can be expected to enrol in trials and 
in the future to be prescribed such a drug, should one 
become available.9 10 27 This study is different from those 
conducted in other countries such as in the Netherlands28 
or in the USA19 in which AD pathophysiological markers 
are performed in a research setting. Our main finding is 
that the incidence of diagnosed AD at the mild dementia 
and prodromal stages is lower than previously thought. 
We also showed that the use of the latest research criteria 
to diagnose early stage AD in clinical practice is rare. In 
France, the latest reports indicate an incidence of up to 
225 000 new AD cases per year.29 This number accounts 
for all stages of AD and is an estimation from the general 
population. This discrepancy between this previous 
finding of 225 000 new AD cases per year and our result 
of about 10 000 new early AD cases per year can also be 
explained by several points:
1. Our analysis does not include a significant portion of 
the clinical setting in which patients with cognitive 
complaints are evaluated, especially with regards to the 
non-hospital based or neurologists from private prac-
tice. The BNA includes data from only about 90 private 
specialists, providing data on 2.2% of the AD and 2.5% 
of the MCI patients in the BNA. As there are about 800 
French private neuro specialists, although not all so ac-
tive in the field of neurodegenerative disorders, one 
could assume that private specialists consult a large 
additional number of patients for cognitive problems. 
However, thanks to a systematically organised medical 
system with hierarchised and personalised care plan 
and management (figure 2), our results can be gener-
alised to the French AD medical community.30
2. Patients do not consult a specialist when they have MCI 
or mild dementia. One should note that the databases 
analysed in our study only represent the patients di-
agnosed by memory specialists. Our analyses do not 
account for patients who did not consult any physi-
Table 1 Description of the 195 patients from the electronic 
clinical files database
Mean (SD) or N (%)
Age 70.8 (0.6)
Gender—female 108 (55.1)
Educational level (years of education) 10.7 (0.4)




Aß1–42 (pg/mL) 527.7 (11.6)
tau (pg/mL) 672.5 (23.6)
Phosphorylated tau (pg/mL) 110.9 (7.4)
Phosphorylated tau/Aß1–42 ratio 0.21 (0.01)
Caregiver (n=74)
  Spouse 59 (79.7)
  Children 10 (13.5)
  Other 5 (6.8)
Addressed by (n=74)
  Family 8 (13.3)
  General practitioner 29 (48.3)
  Neurologist 17 (28.3)
  Psychiatrist 4 (6.7)
  Other 2 (3.4)
Anti-AD drug (n=60)
  0 12 (20)
  DONEPEZIL 5 mg 2 (3.3)
  DONEPEZIL 10 mg 16 (26.7)
  GALANTAMINE 16 mg LP 3 (5)
  GALANTAMINE 24 mg LP 6 (10)
  RIVASTIGMINE 12 mg 2 (3.3)
  RIVASTIGMINE 4.6 mg patch 2 (3.3)
  RIVASTIGMINE 9.5 mg patch 17 (28.3)
  Included in a clinical trial 100 (51)
AD, Alzheimer’s disease; CMRR, Centres de mémoire, 
de recherche et de ressources (Centres for Research and 
Resources on Memory);  FCSRT, free and cued selective 
reminding test; MMSE, mini mental state examination.
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cian nor for those who consulted their general practi-
tioner and were not referred to a specialist. It has been 
shown in the 3C study31 that among the 201 subjects 
with ‘prevalent dementia’, 61.4% consulted a general 
practitioner for a ‘cognitive problem’ and 32.9% con-
sulted a specialist.32 After 80 years of age, only 19.7% of 
this elderly population did consult a memory special-
ist. This is also the case in other countries. In Finland, 
48.2% of demented patients in the study by Lopponen 
et al had previously been diagnosed by a physician.33 
This percentage decreased to 33% when the MMSE 
was >20. This underdiagnosis of AD and dementia has 
also been found in population studies in Sweden,34 
Great Britain,35 Canada36 and the USA.37 There are 
many reasons for the underdiagnosis of dementia, 
from the slowness of the cognitive changes38 to the 
fearful/fatalistic attitude regarding this irreversible 
disease. Moreover, general practitioners do not often 
refer their patients to a neuro specialist as only 41% of 
them consider that the specific treatments of AD are 
efficient.39 These two first points are important to con-
sider as a selection bias. Of course, our data are not 
representative of the overall French incidence of early 
stages AD in 2014 and 2015 but only of diagnosed cas-
es, that is, individuals who either by themselves or due 
to a caregiver or physician came to have a neurological 
evaluation. No data exist yet in France to address the 
discrepancy between the total number of early stages 
AD and the diagnosed cases. The French cohort CON-
STANCES, aiming to recruit 200 000 individuals ran-
domly selected from a population and to follow them 
for 5 years with a yearly cognitive assessment for elderly 
participants and AD diagnosis recording will allow re-
searchers to address this critical point.40 This contrast 
between clinical and population-based data will be the 
subject of further studies.
3. Many patients are already in an advanced dementia 
stage when they consult for the first time. In the BNA, 
the mean (±SD) MMSE score at the time of AD diagno-
sis was found to be 18.9 (±5.5).41
4. The thresholds chosen to ascertain episodic memory 
impairment of the hippocampal type or AD CSF pro-
file may be too strict, thus resulting in some false-neg-
ative subjects.
5. The decision to exclude ‘mixed dementia’ patients 
from our analyses can certainly account for a low-
er number of AD patients who may be eligible for a 
drug trial. This choice was made to be as close as pos-
sible to the current trial inclusion criteria although, 
should one disease-modifying drug become available, 
the decision to treat these patients or not will have to 
be made on a case by case basis and foster new trials. 
As already reported in other studies, focusing on the 
generalisability of clinical trial criteria in community 
samples,42 the stricter the eligibility criteria, the less 
generalisable the trial is. As it is, this criteria will severe-
ly limit the broad application of a disease-modifying 
treatment, should one become available in the coming 
years. There is a balance to be found between eligibil-
ity criteria that should on one hand yield an optimal 
internal validity to a trial and on the other hand, would 
accurately reflect treatment effect in clinical settings.43
6. Biomarker data as required by IWG-2 criteria are avail-
able in clinical setting to only a minority of patients. In 
Table 2 New patients with Alzheimer’s disease in the National Alzheimer Database (BNA) in 2014 and 2015 stratified by 
MMSE values
N (%) 2014 (n=119 493) 2015 (n=113 585)
Clinical 
syndrome Type of clinic MMSE <20 MMSE ≥20 MMSE <20 MMSE ≥20
AD Primary memory clinic 10 534 (60.00) 7018 (40.00) 8363 (62.00) 5137 (38.10)
CMRR 2365 (54.80) 1953 (45.20) 2073 (53.90) 1776 (46.10)
Private neurologist 259 (45.30) 313 (54.70) 176 (44.00) 224 (56.00)
Total AD 13 158 (53.37) 9284 (46.63) 10 612 (53.30) 7137 (46.73)
aMCI Primary memory clinic 183 (6.40) 2668 (93.60) 197 (6.90) 2669 (93.10)
CMRR 47 (4.50) 994 (95.50) 30 (3.30) 889 (96.70)
Private practice neurologist 5 (2.40) 200 (97.60) 3 (2.40) 121 (97.60)
Total aMCI 235 (4.43) 3862 (95.57) 230 (4.20) 3679 (95.80)
naMCI Primary memory clinic 256 (6.30) 3807 (93.70) 256 (6.90) 3467 (93.10)
CMRR 72 (4.10) 1669 (95.90) 73 (4.30) 1612 (95.70)
Private neurologist 2 (0.90) 225 (99.10) 5 (3.90) 125 (96.20)
Total naMCI 330 (3.77) 5701 (96.23) 334 (5.03) 5204 (95.00)
Grand total 13 723 (20.52) 18 847 (79.48) 11 176 (20.84) 16 020 (79.18)
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CMRR, Centres de mémoire, de recherche et de ressources (Centres for 
Research and Resources on Memory); MMSE,  Mini Mental State Evaluation; naMCI, non-amnestic mild cognitive impairment.
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the 11 expert centres of our study, we estimate that they 
were performed in 10% of the prodromal to mild AD 
group. CSF AD biomarker sampling through lumbar 
puncture, although authorised in the national health 
guidelines on AD diagnosis, is not systematically per-
formed on all patients with a possible diagnosis of AD. 
The actual recommendations from the French health 
authorities stipulate that these biomarkers are espe-
Table 4 Comparison between two groups of patients diagnosed with AD or MCI in the BNA in 2014 either in the 11 CMRRs 
participating in the detailed analysis (Group 1) or in the 18 other French CMRRs
CMRRs
P value
Group 0 (n=5 124) Group 1 (n=3 471)
Mean (SD) Mean (SD)
Age 78.12 (10.27) 74.52 (12.07) <0.001
MMSE 20.85 (6.65) 21.71 (6.52) <0.001
n (%) n (%) P value
Gender <0.001
  Female 3314 (64.7) 2080 (59.9)
  Male 1810 (35.3) 1391 (40.1)
Diagnostic <0.001
  AD 3195 (62.4) 1804 (52.0)
  aMCI 595 (11.6) 592 (17.1)
  naMCI 1045 (20.4) 906 (26.1)
  AD and aMCI 118 (2.3) 105 (3.0)
  AD and aMCI and naMCI 19 (0.4) 9 (0.3)
  aMCI and naMCI 152 (3.0) 55 (1.6)
First MMSE <0.001
  <20 1680 (35.9) 825 (28.8)
  ≥20 3000 (64.1) 2039 (71.2)
Education level <0.001
  <12 years 2827 (55.1) 1889 (54.5)
  >12 years 1806 (35.3) 1238 (35.5)
  Missing data 461 (9.6) 350 (10)
Referred to the CMRR by <0.001
  General practitioner 2978 (58.1) 1838 (53.0)
  Neurologist 413 (8.1) 665 (19.2)
  Psychiatrist 102 (2.0) 49 (1.4)
  Geriatrician 243 (4.7) 175 (5.0)
  Other specialist 573 (11.2) 214 (6.2)
  Direct 387 (7.6) 226 (6.5)
  Retirement home 49 (1.0) 26 (0.8)
  Primary memory clinic 17 (0.3) 31 (0.9)
  Other CMRR 24 (0.5) 34 (1.0)
  Hospitalisation unit 310 (6.1) 198 (5.7)
  Emergency unit 12 (0.2) 8 (0.2)
  Social care services 16 (0.3) 7 (0.1)
Group 0 (18 CMRR): Bordeaux, Clermont-Ferrand, Caen, Brest, Rennes, Reims, Corse, Besançon, Paris-Broca, Montpellier, Limoges, 
Toulouse, Marseille, Angers, Amiens, Grenoble, Villeurbanne, Saint-Etienne.
Group 1 (11 CMRR): Dijon, Lille, Nantes, Vandœuvre-Lès-Nancy, Nice, Paris -Lariboisière, Paris–Pitié Salpêtrière, Poitiers, Rouen, Strasbourg, 
Tours.
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; CMRR, Centre for memory research and resource; MCI, mild cognitive 
impairment; MMSE, Mini Mental State Evaluation; naMCI, non-amnestic mild cognitive impairment.
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cially useful in young onset dementia and dementia 
with an atypical presentation, not in MCI or in patients 
with a typical clinical AD dementia profile. Indeed, 
a previous study, also conducted in France, showed 
that these markers are mainly used in cases of atypi-
cal dementia or diagnostic uncertainty.44 This explains 
the relatively young age of the 195 patients (mean: 
70.8 year) when compared with a previously published 
mean age of 80.9 years of all AD patients in the BNA.41 
Considering our findings, we can argue that CSF bio-
markers be used more frequently in expert memory 
centres as they have been described to provide good 
accuracy for AD diagnosis in clinical practice45 and in-
fluence clinicians in their decision-making processes.46 
Since March 2016, a new BNA version has been imple-
mented. Clinicians are now asked to answer questions 
concerning the main syndromic alteration observed 
(in memory, language, praxis, executive functions, or 
visuospatial ability), the stage of the patient (wheth-
er they have a subjective complaint, MCI or a major 
cognitive disorder) and the probable aetiology of the 
cognitive impairment. They are also asked if AD aetiol-
ogy is supported by a biomarker measurement or not. 
This new paradigm will allow for a finer delineation 
of the epidemiology of early stage AD and will be the 
focus of future studies. We focused on cognitive and 
CSF markers of AD in this study and not on amyloid 
or fluorodeoxyglucose (FDG) positron emission to-
mography (PET) or MRI because of two main reasons. 
First, amyloid PET is not routinely available in French 
clinics, whereas CSF biomarkers are. Second, MRI and 
FDG PET are topographic markers with lower specific-
ity than CSF biomarkers. The choice of the association 
of cognition and CSF markers to ascertain the diagno-
sis of AD is consistent with the IWG-2 criteria. This is 
also in line with the recently revised NIA AA criteria 
based on Jack et al. A/T/N classification which states 
that MRI and FDG PET can be used to diagnose ‘neu-
rodegeneration’ considered not specific to AD.47 48
7. Finally, a worldwide decrease in the incidence of 
AD has been described in a number of independent 
studies,49–51 possibly linked to an improvement of the 
general health risk factors and a higher education lev-
el in the countries from which these cohorts derive. 
Nevertheless, this element most probably could only 
explain a small part of the discrepancy.
In a post-hoc survey conducted in the 11 participating 
CMRRs, the main reasons mentioned to explain the small 
number of identified patients eligible for a disease-mod-
ifying drug trial were the absence of referral of AD 
Figure 2 Clinical path of a patient consulting for a cognitive complaint in France. This scheme details the hierarchised 
and personalised strategy proposed for any given new patient. CJD, Creutzfeldt Jakob disease; CSF, cerebrospinal fluid; 
DSM, Diagnostic statistical manual; EEG, electroencephalography; FTD, fronto-temporal dementia; Geriat, Geriatrician; GP, 
General Practitioner; I II III prevention, primary, secondary and tertiary prevention; Neuro, Neurologist; PET, positron emission 
tomography; Psy, Psychiatrist; SPECT, single photon emission CT.
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patients at an early stage of the disease, the fact that the 
lumbar puncture is not recommended in typical amnestic 
AD unless it occurs before 65 years of age, and the fact 
that some patients could have AD and not be within the 
chosen cognitive thresholds for this study.
Interestingly, the 195 patients identified with 
prodromal or mild AD in the 11 CMRRs, which are part 
of the third-line healthcare organisation, had been most 
often referred by their general practitioners, whereas 
one would expect they would be referred mainly by 
neuro specialists in the second line. This lack of ‘special-
ised referral’ is also supported by the small geographical 
distance (40.1±6.7 km) separating these patients from the 
CMRR.
This study has limitations including its retrospective 
design for the electronic record file database that does 
not allow us to draw definitive epidemiological conclu-
sions, but still raises the level of awareness concerning 
the relatively low diagnostic rate of AD at its early clinical 
stage.
Another limitation is that our study, so far and to our 
knowledge, cannot be generalised to other countries 
because we lack recent epidemiological data on AD on 
the same scale as our study. Results from these studies52 
are usually derived from cohorts recruited in the 1990s 
or 2000s and not these last years. This fact alone is trou-
blesome both because of the suggested trend in AD inci-
dence decrease in these last decades50 51 and because the 
recruitment in these cohorts predates the newest diag-
nostic criteria for AD.3 5 15 Finally, early AD is never indi-
vidualised in these studies focusing on AD whatever the 
severity at diagnosis. Also, the use of biomarkers is never 
disclosed in these epidemiological studies.
COnClusiOns
Our study is the first and largest to address the critical 
question of the frequency of a specific AD diagnosis at 
its early stages in clinical routine. Our estimations of the 
incidence of clinically diagnosed prodromal or mild AD 
are only a fraction of previous incidence estimations of 
AD in the general population.29 This finding, which is 
based on two different database analyses, is generalisable 
on a national scale due to the large number of included 
participants and the 5-year period of evaluation. Similar 
findings will have to be evidenced in other countries to 
be able to generalise these results on a global scale. This 
topic is important to consider since new disease-modifying 
drugs, specifically designed to target this population of 
patients, may become available in the coming years. If the 
ongoing trials yield positive results, we will be confronted 
with an unprecedented ‘rush towards treatment’ from 
a huge number of patients. These treatments should, 
however, only be proposed to patients if there is potential 
expected efficacy. Thus, the selection of patients, fitting 
the successful trial’s inclusion criteria, should be identi-
fied by expert centres. Also, new diagnostic tests such as 
amyloid PET, which has recently been proved to change 
the care and management plan in >60% of patients with 
MCI or dementia53 or amyloid sampling in blood,54 may 
transform the diagnostic procedures of patients with 
cognitive complaints or impairments in the near future. 
Large efforts will have to be made in order to improve the 
diagnostic procedures, and access to these procedures, 
for patients at an early stage of AD. National databases 
are valuable tools to monitor these diagnostic procedures 
and improve them.
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